Viridian Therapeutics, Inc./DE Paid-in-Kind Interest
Viridian Therapeutics, Inc./DE (VRDN) reported Paid-in-Kind Interest of $4.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE paid-in-kind interest for the quarter ending 2026-06-30 was $2.54M, a 2364.08% increase year-over-year.
- Viridian Therapeutics, Inc./DE paid-in-kind interest for the quarter ending 2026-03-31 was $2.34M, a 2175.73% increase year-over-year.
- Viridian Therapeutics, Inc./DE paid-in-kind interest for the quarter ending 2025-12-31 was $2.26M, a 3727.12% increase year-over-year.
- Viridian Therapeutics, Inc./DE paid-in-kind interest for the quarter ending 2025-09-30 was $102.00K.
- Viridian Therapeutics, Inc./DE paid-in-kind interest for fiscal 2025 was $2.57M, a 580.64% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE paid-in-kind interest for fiscal 2024 was $377.00K, a 18.93% increase from fiscal 2023.
- Viridian Therapeutics, Inc./DE paid-in-kind interest for fiscal 2023 was $317.00K.
- Viridian Therapeutics, Inc./DE paid-in-kind interest for fiscal 2016 was $93.00K, a 29.55% decline from fiscal 2015.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 6 month as first filed | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 9 month as first filed | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.88M 10-Q · filed 2026-08-06 | $7.14M derived: sum of 3 quarters · filed 2026-08-06 | $7.24M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.34M 10-Q · filed 2026-05-05 | $4.60M derived: sum of 2 quarters · filed 2026-05-05 | $4.70M derived: sum of 3 quarters · filed 2026-05-05 | $4.81M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.36M derived: sum of 2 quarters · filed 2026-02-26 | $2.46M derived: sum of 3 quarters · filed 2026-08-06 | $2.57M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $205.00K derived: sum of 2 quarters · filed 2026-08-06 | $308.00K 10-Q · filed 2025-11-05 | $367.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $206.00K 10-Q · filed 2026-08-06 | $265.00K derived: sum of 3 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $103.00K 10-Q · filed 2026-05-05 | $162.00K derived: sum of 2 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $377.00K 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $318.00K 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $317.00K 10-K · filed 2026-02-26 | |||||
| 2016-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $49.00K derived: sum of 2 quarters · filed 2017-03-24 | $71.00K derived: sum of 3 quarters · filed 2017-03-24 | $93.00K 10-K · filed 2017-03-24 | ||
| 2016-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $44.00K derived: sum of 2 quarters · filed 2016-10-26 | $66.00K 10-Q · filed 2016-10-26 | $88.00K derived: sum of 4 quarters · filed 2017-03-24 | ||
| 2016-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $44.00K 10-Q · filed 2016-08-15 | $66.00K derived: sum of 3 quarters · filed 2017-03-24 | $88.00K derived: sum of 4 quarters · filed 2017-03-24 | ||
| 2016-03-31 | $22.00K 10-Q · filed 2016-05-16 | $44.00K derived: sum of 2 quarters · filed 2017-03-24 | $66.00K derived: sum of 3 quarters · filed 2017-03-24 | $134.00K derived: sum of 4 quarters · filed 2017-03-24 | ||
| 2015-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $44.00K derived: sum of 2 quarters · filed 2017-03-24 | $112.00K derived: sum of 3 quarters · filed 2017-03-24 | $132.00K 10-K · filed 2017-03-24 | ||
| 2015-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $90.00K derived: sum of 2 quarters · filed 2016-10-26 | $110.00K 10-Q · filed 2016-10-26 | $109.00K derived: sum of 4 quarters · filed 2016-10-26 | ||
| 2015-06-30 | $68.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $88.00K 10-Q · filed 2016-08-15 | $87.00K derived: sum of 3 quarters · filed 2016-08-15 | $87.00K derived: sum of 4 quarters · filed 2016-08-15 | ||
| 2015-03-31 | $20.00K 10-Q · filed 2016-05-16 | $19.00K derived: sum of 2 quarters · filed 2016-05-16 | $19.00K derived: sum of 3 quarters · filed 2016-05-16 | $495.00K derived: sum of 4 quarters · filed 2016-05-16 | ||
| 2014-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | -$1.00K derived: sum of 2 quarters · filed 2016-03-21 | $475.00K derived: sum of 3 quarters · filed 2016-03-21 | $1.01M 10-K · filed 2016-03-21 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $476.00K derived: sum of 2 quarters · filed 2015-11-13 | $1.01M 10-Q · filed 2015-11-13 | $1.01M 10-Q · filed 2014-11-14 | $1.46M derived: sum of 4 quarters · filed 2015-11-13 | |
| 2014-06-30 | $476.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.01M 10-Q · filed 2015-08-14 | $1.01M 10-Q · filed 2014-08-14 | $1.46M derived: sum of 3 quarters · filed 2015-08-14 | $2.02M derived: sum of 4 quarters · filed 2015-08-14 | |
| 2014-03-31 | $532.00K 10-Q · filed 2015-05-15 | $984.85K derived: sum of 2 quarters · filed 2015-05-15 | $1.55M derived: sum of 3 quarters · filed 2015-05-15 | |||
| 2013-12-31 | $452.85K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $1.01M derived: sum of 2 quarters · filed 2015-03-27 | $1.94M 10-K · filed 2015-03-27 | |||
| 2013-09-30 | $560.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $1.48M 10-Q · filed 2014-11-14 | ||||
| 2013-06-30 | $923.90K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |